Key result
Class III obesity linked to ~680% higher intraoperative complication rates versus overweight patients during antireflux surgery.
Why the study?
Although bariatric surgery is typically recommended for patients with obesity referred for antireflux surgery, straightforward antireflux surgery is sometimes offered, prompting a comparison of surgical and patient-reported outcomes.
Does minimally invasive antireflux surgery have a favorable safety and efficacy profile across different BMI classes in overweight and obese patients?
Cohort (n=338)
No
Does minimally invasive antireflux surgery have a favorable safety and efficacy profile across different BMI classes in overweight and obese patients?
Minimally invasive antireflux surgery provides a favorable safety profile and symptom control for overweight and non-morbidly obese patients, but is associated with higher perioperative morbidity in class III obesity.
Answers are grounded in this paper and cite their sources.
May warrant ARS consideration in class II obesity when bariatric surgery unavailable; leaves open durability and safety questions in morbid obesity.
Background As the worldwide prevalence of obesity increases, more patients with obesity are referred for antireflux surgery (ARS). Although bariatric surgery is typically recommended, at times straightforward ARS is offered. We aimed to compare surgical and patient-reported outcomes among overweight and obese patients undergoing minimally invasive ARS. Methods This retrospective cohort study included consecutive patients with BMI ≥ 25 kg/m 2 who underwent primary elective ARS by an experienced foregut surgeon (September 2016–June 2025). Patients were stratified by BMI: overweight 25–30, class I obesity 30–35, class II obesity 35–40, and class III obesity ≥ 40 kg/m 2 . Exclusions included prior foregut procedures or non-fundoplication ARS (e.g., magnetic sphincter augmentation). Outcomes of interest were perioperative morbidity, hernia recurrence, midterm quality-of-life scores, and patient satisfaction. Results A total of 338 patients (71.6% female; median age: 65.1 [54.6–73.1] years) were stratified into the BMI groups: overweight ( n = 172, 50.9%), class I ( n = 125, 36.9%), class II ( n = 30, 8.9%), and class III ( n = 11, 3.3%). Intraoperative complication rates (3.5, 4.8, 3.3, and 27.3%; p = 0.006) and ICU admission rates (1.7, 4, 3.3, and 18.2%; p < 0.026) were significantly higher, and early postoperative complications were slightly higher (7.6, 8.8, 6.7, and 27.3%; p = 0.153) in the class III obesity group. Follow-up ≥ 12 months was available for 95/172 (55.2%), 64/125 (51.2%), 15/30 (50%), and 3/11 (27.3%) patients per group with similar median durations (24–36 months). Objective hiatal hernia recurrence (> 2 cm) was observed in 1 overweight and 2 class-I patients, but no class-II/III patients. Improved quality-of-life (GERD-HRQL) scores and high patient satisfaction, especially in the 25–40 kg/m 2 BMI groups, were reported. Conclusion Minimally invasive ARS provides a favorable safety profile along with gastroesophageal reflux control and improved quality of life for overweight and non-morbidly obese patients. Particularly, straightforward ARS for patients with class II obesity may be considered when limitations on bariatric surgery exist.
No takes yet. Share an insight, caveat, or question.
Latorre‐Rodríguez et al. (2026) conducted a cohort in Gastroesophageal reflux disease (GERD) (n=338). Class III obesity (BMI ≥ 40 kg/m2) vs. Overweight (BMI 25-30 kg/m2) was evaluated on Intraoperative complications (p=0.006). Class III obesity was associated with higher intraoperative complication rates compared to overweight patients undergoing minimally invasive antireflux surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: